Radical cystectomy patients faced long hospital stays and complications that could lead to readmissions. Cleveland Clinic has overhauled perioperative management, and decreased lengths of stay, readmissions, postsurgery ED visits – and costs. Research is ongoing.
Connect with our staff at the following poster sessions and roundtable at the 2017 ASRM Annual Meeting.
This short video illustrates a few of the reasons Cleveland Clinic urology (Glickman Urological & Kidney Institute) has been cited as No. 1 in the nation in U.S. News & World Report rankings.
Study suggests that novel prostate-specific antigen assay could significantly reduce unnecessary biopsies and help urologists provide men with the information needed to make informed decisions.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
With this year’s No. 2 overall ranking, Cleveland Clinic has been ranked among the country’s Top 5 hospitals for 19 consecutive years.
Cleveland Clinic urologic oncologist and researcher Byron Lee, MD, PhD, has received two significant awards recognizing his research in chromatin modifier genes and bladder cancer: a Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research and a Young Investigator Award from the Bladder Cancer Advocacy Network.
Cleveland Clinic research findings suggest that effective steroidal antiandrogens share common metabolic activities and metabolites should be closely examined for effects on tumor survival.
An analysis of 10,533 kidney transplant recipients shows 57 percent visit an emergency department within two years of transplantation, and half are hospitalized. Authors recommend improved education for patients and ED providers.
Surgeons have performed the first kidney transplant at Cleveland Clinic Abu Dhabi. The living related donor procedure this spring heralds the medical center’s development of a comprehensive transplant center.
New evidence shows that men on active surveillance of prostate cancer can safely wait at least five years between surveillance biopsies. Study authors hope new findings increase appeal of disease monitoring and reduce patient and provider anxiety.